{
  "id": 97121,
  "title": "AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger",
  "url": "https://urgent.news/2026/08/03/astrazeneca-should-stick-to-its-winning-formula-it-doesnt-need-a",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-03T17:22:28.000Z",
  "source": {
    "name": "Guardian Business",
    "slug": "guardian-business",
    "url": "https://www.theguardian.com/business/2026/aug/03/astrazeneca-should-stick-to-winning-formula-doesnt-need-400bn-us-mega-merger"
  },
  "original_language": "en",
  "account": null,
  "summary": "The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling • AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of AstraZeneca, starts with huge credit in the bank, obviously. His long tenure has been a triumph, starting with the against-the-odds victory over Pfizer’s charmless accountants in…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}